HPV Vaccination in Women With Cystic Fibrosis (VACCIN-HPV-MUC)
|ClinicalTrials.gov Identifier: NCT03265743|
Recruitment Status : Completed
First Posted : August 29, 2017
Last Update Posted : February 16, 2018
The main risk factor for the development of cervical lesions is human papillomavirus (HPV) infection. Vaccination against human papillomavirus, which is offered to all girls aged 11 to 14, and catching up to girls aged 15 to 19, is an effective method of preventing cervical pathology. Despite this, human papillomavirus vaccination coverage remains low in France.
Some women with cystic fibrosis might need a transplantation, which is a factor associated with increased risk of human papillomavirus carriage and cervical pathology. An over-risk of cervical pathology would also be present in non-transplanted women with cystic fibrosis. Particular attention should therefore be paid to vaccination in this population.
The objective is to estimate the frequency of human papillomavirus vaccination in young patients with cystic fibrosis, and to evaluate the reasons for non-vaccination.
|Condition or disease||Intervention/treatment|
|Human Papillomavirus Infection||Other: Self-report Written Questionnaire|
|Study Type :||Observational|
|Actual Enrollment :||74 participants|
|Official Title:||HPV (Papilloma Human Virus) Vaccination in Young Women With Cystic Fibrosis and Followed in the Auvergne Rhône-Alpes Region|
|Actual Study Start Date :||September 25, 2017|
|Actual Primary Completion Date :||December 15, 2017|
|Actual Study Completion Date :||December 15, 2017|
Patients with Cystic Fibrosis
Patients with Cystic Fibrosis, followed in a pediatric or mixed Cystic Fibrosis center of the region Auvergne Rhône Alpes (AuRA), aged 11 years or older.
Other: Self-report Written Questionnaire
Informations are gathered through a self-report written questionnaire, completed by the patients or their parents.
- Realization of human papillomavirus vaccination [ Time Frame: 15 minutes ]
The main outcome is the prevalence of human papillomavirus vaccination in young women with Cystic fibrosis.
This data is collected using a questionnaire : HPV vaccination performed : yes/no
- Type of vaccine used [ Time Frame: 15 minutes ]This data is collected using a questionnaire : bivalent (Cervarix®) or quadrivalent (Gardasil®)
- Respect for the vaccinal plan [ Time Frame: 15 minutes ]This data is collected using a questionnaire : number and dates of injections
- Reasons for non-vaccination [ Time Frame: 15 minutes ]In case of non-vaccination reasons are collected using a multiple choices questionnaire
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03265743
|Nouvel Hôpital d'Estaing CRCM Mixte|
|Clermont-Ferrand, France, 63003|
|Grenoble, France, 38043|
|Cystic Fibrosis Reference Center, Hospices Civils de Lyon|
|Pierre-Bénite, France, 69495|